Brief: Genfleet Therapeutics (Shanghai) Says GFH375 Advances To Registrational Phase III Study In China
10/08/2026 02:10
BRIEF-Genfleet Therapeutics (Shanghai) Says GFH375 Advances To Registrational Phase III Study In China Aug 10 (Reuters) - GenFleet Therapeutics (Shanghai) Inc 2595.HK:
GFH375 ADVANCES TO REGISTRATIONAL PHASE III STUDY IN CHINA FOR KRAS G12D-MUTANT NSCLC
Further company coverage: 2595.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GenFleet Therapeutics (Shanghai)
See all newsHK-listed GenFleet jumps on positive progress of cancer drug
GenFleet hits over 3-week high as cancer drug makes progress on BTD list
Brief: GenFleet Therapeutics (Shanghai) Says GFH375 Combined With Cetuximab Placed On Proposed BTD List
HK-listed GenFleet rises most in a month on repurchasing shares
Brief: GenFleet Therapeutics (Shanghai) Reports Loss Of RMB220.17 Million For Six Months